Long-Term Insights for Type 1 Diabetes
Type 1 Diabetes Extension Study
Recruiting
Observational Study
Type 1 Diabetes Mellitus
T1DM
T1D
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 8 – 35
- Sex
- Any
- Study type
- Observational
- Participants needed
- 111 (estimated)
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID) · NIH
Who this trial is looking for
This trial is looking for people who have previously participated in a type 1 diabetes study. Taking part means we will follow you to see how long you continue to produce insulin and how your immune system changes over time.
Are You a Good Fit for This Trial?
You may be able to join if
- I have previously participated in a type 1 diabetes study.
- I can sign the consent form myself or have permission if I am a child.
You may not be able to join if
- I have a medical condition that would make it unsafe for me to take part.
- I cannot keep up with the study visit schedule.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D).
This observational study will:
* follow participants to determine how long they continue to produce insulin, and
* will also assess how changes in the immune system over tim…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Prior participant in an Immune Tolerance Network (ITN) executive committee approved T1DM study.
* Ability to sign informed consent/assent (as applicable for children).
Exclusion Criteria:
* Any medical condition that in the opinion of the principal investigator would interfe…
Contacts
No contact information available.